nn_logo_cmyk_blue_small.jpg
European regulatory authority adopts a positive opinion for an update of the Wegovy® label to reflect risk reduction of major adverse cardiovascular events
July 25, 2024 11:08 ET | Novo Nordisk A/S
Bagsværd, Denmark, 25 July 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S - share repurchase programme
July 22, 2024 08:22 ET | Novo Nordisk A/S
Bagsværd, Denmark, 22 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S - share repurchase programme
July 15, 2024 06:50 ET | Novo Nordisk A/S
Bagsværd, Denmark, 15 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk receives Complete Response Letter in the US for once-weekly basal insulin icodec
July 10, 2024 17:45 ET | Novo Nordisk A/S
Bagsværd, Denmark, 10 July 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) covering the Biologics License Application for...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S - share repurchase programme
July 08, 2024 09:18 ET | Novo Nordisk A/S
Bagsværd, Denmark, 08 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S - share repurchase programme
July 01, 2024 09:19 ET | Novo Nordisk A/S
Bagsværd, Denmark, 01 July 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss
June 26, 2024 10:50 ET | Novo Nordisk A/S
Bagsværd, Denmark, 26 June 2024 – Novo Nordisk today announced that the CLARION-CKD phase 3 trial failed to meet its primary endpoint and that it will recognise an impairment loss of around DKK 5.7...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk announces 4.1 billion USD investment to expand US manufacturing capacity
June 24, 2024 14:16 ET | Novo Nordisk A/S
In 2024, Novo Nordisk plans to boost its current investments, aiming to allocate USD 6.8 billion towards production, a significant increase from the previous year's investment of USD 3.9 billion*. ...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S - share repurchase programme
June 24, 2024 08:55 ET | Novo Nordisk A/S
Bagsværd, Denmark, 24 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S: Mim8 demonstrated superior reductions in annualised bleeding rate (ABR) compared to on-demand and prior prophylaxis treatment in people with haemophilia A
June 23, 2024 01:01 ET | Novo Nordisk A/S
FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had no prior prophylaxis treatment, experienced zero treated bleeds while on Mim8 Bagsværd, Denmark, 23 June 2024 – Novo...